---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-056424"
form_type: "8-K"
ticker: "NWBO"
cik: "0001072379"
company_name: "NORTHWEST BIOTHERAPEUTICS INC"
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-02T23:51:39.242226+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Northwest Biotherapeutics enters $11M loan agreement with Streeterville Capital

## Summary
- Loan principal of $11,005,000; maturity 22 months; repayments begin Dec 26, 2024.
- 14 equal monthly installments at 110% of pro rata plus accrued interest (8% per annum).
- 10% original issue discount; prepayment allowed with 10% charge.
- Proceeds fund business ops, construction of first grade C lab in Sawston UK, long lead-time equipment, Flaskworks prep.

## SEC filing metadata
- accession: 0001104659-24-056424
- form_type: 8-K
- ticker: NWBO
- cik: 0001072379
- company_name: NORTHWEST BIOTHERAPEUTICS INC
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1072379/000110465924056424/0001104659-24-056424-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1072379/000110465924056424/tm2413348d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-056424
- JSON: https://secwatch.observer/filing/0001104659-24-056424.json
- Plain text: https://secwatch.observer/filing/0001104659-24-056424.txt

## Key facts
- Debt Financings
  NORTHWEST BIOTHERAPEUTICS INC incurred loan of $11,005,000 with Streeterville Capital, LLC at 8% per annum maturing 22 months.
  - Instrument: loan
  - Principal: $11,005,000
  - Counterparty: Streeterville Capital, LLC
  - Rate: 8% per annum
  - Maturity: 22 months
  - Event: incurrence
  source text: On April 26, 2024, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1072379/000110465924056424/0001104659-24-056424-index.htm
- Material Agreements
  NORTHWEST BIOTHERAPEUTICS INC entered into Loan Agreement with Streeterville Capital, LLC valued at $11,005,000 (effective 2024-04-26).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Streeterville Capital, LLC
  - Value: $11,005,000
  - Effective: 2024-04-26
  source text: On April 26, 2024, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1072379/000110465924056424/0001104659-24-056424-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.